Clinical Trials Browser

Terminated × INDUSTRY × tenalisib × Clear all

NCT03471351 2019-12-27

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Phase 1 Terminated

Hodgkin Disease